Memorial Hospital Research Laboratories

The Thomas Reiner Lab

Research

Thomas Reiner, PhD

The Reiner Lab research program revolves around the development, validation and translation of novel imaging agents. Our research is firmly rooted in the preclinical research space, but we also aggressively pursue translational clinical projects. One of our key achievements is the development of a quantitative small molecule imaging platform for PARP1, yielding several translated imaging agents that have originated in our lab. One of our imaging agents, PARPi-FL, a fluorescent intraoperative probe, entered clinical trials in March 2017 (IND#133,109, NCT03085147). A second translated drug, [¹⁸F]PARPi, a quantitative PET imaging agent, was approved for clinical trials in August 2018 and November 2019 (IND#139974; NCT03631017 and NCT04173104, respectively). Phase I data for both agents has been published in Nature Biomedical Engineering (Kossatz et al 2020) and Clinical Cancer Research (Schöder et al, 2020). A radiotherapeutic version of our PARP1 imaging agents is being tested in mouse models of cancer.

While our previous work was in large part focused on the detection, delineation and treatment of cancer, we also interrogate other physiologically relevant markers. These agents help us to understand the molecular mechanisms of drug action, shedding new light on tumor cell pathology and helping to predict why some patients respond well to a particular treatment regimen, while others do not.

View Lab Overview

Publications

Kossatz S, Pirovano G, Demétrio DSFP, Strome A, Sunny S, Zanoni D, Mauguen A, Carney B, Brand C, Shah V, Ramanajinappa RD, Hedne N, Birur P, Sihag S, Ghossein RA, Gonen M, Strome M, Suresh A, Kuriakose M, Ganly I, Patel S, Reiner T. Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nature biomedical engineering. 2020;4(3):272.

Schöder H, França PDS, Nakajima R, Burnazi E, Roberts S, Brand C, Grkovski M, Mauguen A, Dunphy MP, Ghossein RA, Lyashchenko SK, Lewis JS, O’Donoghue JA, Ganly I, Patel SG, Lee NY, Reiner T. Safety and Feasibility of PARP1/2 Imaging with (18)F-PARPi in Patients with Head and Neck Cancer. Clin Cancer Res. 2020;26(13):3110-6.

View All Publications

People

Thomas Reiner, PhD

Chemist and imaging specialist Thomas Reiner develops and translates imaging agents and radiotherapeutics for earlier and improved diagnosis, stratification and treatment of malignant tumors.
PhD, Technical University of Munich, Germany

reinert@mskcc.org: Email Address
646-888-3461: Office Phone
View physician profile: Physician profile

Members

Paula Demetrio De Souza Franca
Visiting Investigator

Lab Alumni

Christian Brand

Postdoctoral Research Fellow

Giuseppe Carlucci
Postdoctoral Research Fellow

Fabien Emmetiere
Graduate Research Assistant

Beatriz Salinas-Rodriguez
Postdoctoral Research Fellow

Lab Affilations

Open Positions

Career Opportunities

Graduate Students The Reiner Lab welcomes graduates interested in research in chemistry, molecular imaging and radiotherapy.

Apply now

Get in Touch

reinert@mskcc.org

Lab Head Email
646-888-3461

Office Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Thomas Reiner discloses the following relationships and financial interests:

Summit Biomedical Imaging, LLC
Intellectual Property Rights; Ownership / Equity Interests

Theragnostics, Ltd.
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures